Targeting claudins in cancer.

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Epithelial-derived malignancies represent the majority of human tumors, posing significant treatment challenges due to heterogeneity, metastasis, and therapy resistance.
• Claudins, a family of tetra-transmembrane proteins, are crucial regulators of epithelial function and integral components of tight junctions, controlling barrier integrity and cellular organization.

Purpose of the Study:

• To review the evolving landscape of claudin-targeting therapeutics in cancer treatment.
• To examine key advances, emerging challenges, and future prospects in exploiting claudins as therapeutic targets.

Main Methods:

• Review of scientific literature focusing on claudin family proteins in epithelial biology and cancer.
• Analysis of clinical studies and therapeutic developments targeting claudins, including antibody-based therapies.

Main Results:

• Claudin expression is frequently dysregulated in various cancers, indicating their potential as therapeutic targets.
• The development of zolbetuximab, a CLDN-18.2-targeted antibody, represents a significant advancement, recently approved for gastric cancer treatment.
• Targeting claudins holds promise for expanding treatment options for various cancers.

Conclusions:

• Claudin-targeting therapeutics represent a promising frontier in oncology.
• The success of zolbetuximab highlights the therapeutic potential of targeting specific claudins.
• Continued research into claudin biology and targeted therapies is crucial for advancing cancer treatment strategies.